Profile data is unavailable for this security.
About the company
Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is developing proprietary allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses (vaccinia virus and adenovirus) and, potentially, other molecules to cancer patients. It is focused on developing two proprietary stem cell-based platforms and one enveloped vaccinia virus platform designed to protect the oncolytic virus, whether natural or engineered, from neutralization by the patient’s immune defenses, allowing for greater infection of the tumor cells and leading to a potential improvement in the antitumor activity of oncolytic viruses over traditional naked oncolytic virus therapies. Its product candidates include the CLD-101 product for high grade glioma (HGG), CLD-101 product for Recurrent HGG, CLD-201 product for solid tumors, CLD-301 (AAA) for multiple indications and CLD-400 (RTNova) for certain lung cancer and metastatic solid tumors.
- Revenue in USD (TTM)0.00
- Net income in USD-25.62m
- Incorporated2021
- Employees28.00
- LocationCalidi Biotherapeutics Inc4475 Executive Drive, Suite 200SAN DIEGO 92121United StatesUSA
- Phone+1 (858) 794-9600
- Fax+1 (858) 794-9605
- Websitehttps://www.calidibio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mustang Bio Inc | 0.00 | -2.34m | 5.20m | 6.00 | -- | 0.532 | -- | -- | -47.37 | -47.37 | 0.00 | 1.34 | 0.00 | -- | -- | 0.00 | -17.59 | -70.16 | -224.95 | -83.31 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 69.47 | -- | -- | -- |
| Alaunos Therapeutics Inc | 6.00k | -4.03m | 5.22m | 1.00 | -- | 1.84 | -- | 870.41 | -2.29 | -2.29 | 0.0034 | 1.27 | 0.0017 | -- | -- | 6,000.00 | -110.67 | -63.80 | -145.65 | -77.93 | -- | -- | -67,083.34 | -7,084.74 | -- | -- | 0.00 | -- | 100.00 | -- | 86.68 | -- | -- | -- |
| Ernexa Therapeutics Inc | 1.00k | -18.36m | 5.34m | 6.00 | -- | 1.50 | -- | 5,337.25 | -5.32 | -5.32 | 0.0002 | 0.4548 | 0.0001 | -- | 0.0059 | 166.67 | -264.07 | -187.10 | -2,044.59 | -237.72 | 100.00 | -- | -1,834,000.00 | -3,375.91 | -- | -2.73 | 0.00 | -- | 755.88 | -50.61 | -105.47 | -- | -19.54 | -- |
| CTT Pharmaceutical Holdings Inc | 0.00 | -1.67m | 5.48m | 0.00 | -- | 2.74 | -- | -- | -0.0822 | -0.0822 | 0.00 | 0.0346 | 0.00 | -- | -- | -- | -317.28 | 13.49 | -448.83 | 304.48 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3,454.52 | -- | -- | -- |
| MetaVia Inc | 0.00 | -16.22m | 5.55m | 9.00 | -- | 0.6016 | -- | -- | -13.88 | -13.88 | 0.00 | 2.88 | 0.00 | -- | -- | 0.00 | -87.87 | -99.54 | -167.49 | -140.07 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -121.27 | -- | -48.18 | -- |
| Bullfrog AI Holdings Inc | 116.67k | -6.76m | 5.70m | 9.00 | -- | 2.68 | -- | 48.89 | -0.6936 | -0.6936 | 0.0119 | 0.1866 | 0.0319 | -- | -- | 12,963.33 | -184.34 | -- | -233.50 | -- | 18.76 | -- | -5,770.66 | -- | -- | -- | 0.0278 | -- | -100.00 | -- | -31.42 | -- | -- | -- |
| Aptevo Therapeutics Inc | 0.00 | -27.95m | 6.00m | 37.00 | -- | 0.2651 | -- | -- | -306,220.00 | -306,220.00 | 0.00 | 22.67 | 0.00 | -- | -- | 0.00 | -125.64 | -47.17 | -172.77 | -82.66 | -- | -- | -- | -487.43 | -- | -- | 0.00 | -- | -- | -- | -29.38 | -- | -- | -- |
| Aptorum Group Ltd | -100.00bn | -100.00bn | 6.03m | 1.00 | -- | 0.2348 | -- | -- | -- | -- | -- | 3.15 | -- | -- | -- | -- | -- | -33.06 | -- | -31.53 | -- | 1.65 | -- | -1,009.86 | -- | -- | 0.2079 | -- | -100.00 | -- | -51.09 | -- | -- | -- |
| Calidi Biotherapeutics Inc | 0.00 | -25.62m | 6.04m | 28.00 | -- | 0.8406 | -- | -- | -9.62 | -9.62 | 0.00 | 1.00 | 0.00 | -- | -- | 0.00 | -194.84 | -- | -1,279.90 | -- | -- | -- | -- | -- | -- | -58.24 | 0.1544 | -- | -- | -- | 18.49 | -- | -- | -- |
| enVVeno Medical Corp | 0.00 | -21.97m | 6.13m | 37.00 | -- | 0.1834 | -- | -- | -37.84 | -37.84 | 0.00 | 50.98 | 0.00 | -- | -- | 0.00 | -53.09 | -52.36 | -56.24 | -55.28 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.22 | -- | -36.69 | -- |
| Creative Medical Technology Holdings Inc | 6.00k | -5.96m | 6.22m | 4.00 | -- | 0.8215 | -- | 1,036.75 | -2.87 | -2.87 | 0.0027 | 2.17 | 0.0009 | 1.10 | -- | 1,500.00 | -93.58 | -83.62 | -98.14 | -- | 60.00 | 62.58 | -99,356.66 | -10,541.10 | 20.70 | -- | 0.00 | -- | 22.22 | -41.85 | -3.91 | -- | -- | -- |
| Brainstorm Cell Therapeutics Inc | 0.00 | -10.85m | 6.44m | 27.00 | -- | -- | -- | -- | -1.50 | -1.50 | 0.00 | -0.6973 | 0.00 | -- | -- | 0.00 | -637.06 | -112.30 | -- | -219.11 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 32.39 | -- | -- | -- |
| Aclarion Inc | 67.48k | -7.39m | 6.74m | 6.00 | -- | 0.11 | -- | 99.83 | -1,687.50 | -1,687.50 | 0.1948 | 21.46 | 0.0082 | -- | 2.76 | 11,246.67 | -89.50 | -- | -97.72 | -- | -7.85 | -- | -10,868.49 | -- | -- | -25,428.22 | 0.00 | -- | -39.36 | -- | -43.60 | -- | -- | -- |
| VivoSim Labs Inc | 140.00k | -1.98m | 6.75m | 5.00 | 1.36 | 0.9561 | -- | 48.25 | 1.91 | 1.91 | 0.0226 | 2.71 | 0.017 | -- | 4.59 | 10,769.23 | -24.12 | -51.63 | -34.26 | -56.47 | 98.57 | -- | -1,416.43 | -2,952.99 | -- | -- | 0.00 | -- | 32.11 | -42.01 | 83.04 | -- | -- | -- |
| National Graphite Corp | 0.00 | -1.97m | 6.87m | 0.00 | -- | -- | -- | -- | -0.0221 | -0.0221 | 0.00 | -0.0193 | 0.00 | -- | -- | -- | -11,014.44 | -212.13 | -- | -6,295.18 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1,432.70 | -- | -- | -- |
Data as of Feb 06 2026. Currency figures normalised to Calidi Biotherapeutics Inc's reporting currency: US Dollar USD
6.17%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Hightower Advisors LLCas of 30 Sep 2025 | 84.96k | 2.38% |
| Geode Capital Management LLCas of 30 Sep 2025 | 29.60k | 0.83% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 25.51k | 0.71% |
| Belpointe Asset Management LLCas of 31 Dec 2025 | 19.97k | 0.56% |
| Warberg Asset Management LLCas of 30 Sep 2025 | 18.71k | 0.52% |
| R.S. Crum, Inc.as of 30 Sep 2025 | 15.26k | 0.43% |
| Farther Finance Advisors LLCas of 31 Dec 2025 | 10.00k | 0.28% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 9.22k | 0.26% |
| UBS Securities LLCas of 31 Dec 2025 | 6.00k | 0.17% |
| UBS Switzerland AG (Investment Management)as of 31 Dec 2025 | 1.51k | 0.04% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
